The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Martin FilipitsMargaretha RudasVerena KainzChristian F SingerFlorian FitzalZsuzsanna Bago-HorvathRichard GreilMarija BalićPeter RegitnigStefan HalperWolfgang HullaDaniel EgleStephen BarronTony LoughmanDes O'LearyWilliam M GallagherDominik HlauschekMichael GnantPeter DubskyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
OncoMasTR Risk Score is highly prognostic for DR in postmenopausal women with ER-positive, HER2-negative primary breast cancer with 0 to 3 involved lymph nodes. In combination with prior validation studies, this fully independent validation in ABCSG Trial 8 provides level 1B evidence for the prognostic capability of the OncoMasTR Risk Score.